Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre

Au-Yeung, George, Mileshkin, Linda, Bernshaw, David M., Kondalsamy-Chennakesavan, Srinivas, Rischin, Danny and Narayan, Kailash (2013) Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre. Journal of Medical Imaging and Radiation Oncology, 57 1: 97-104. doi:10.1111/j.1754-9485.2012.02463.x


Author Au-Yeung, George
Mileshkin, Linda
Bernshaw, David M.
Kondalsamy-Chennakesavan, Srinivas
Rischin, Danny
Narayan, Kailash
Title Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre
Journal name Journal of Medical Imaging and Radiation Oncology   Check publisher's open access policy
ISSN 1754-9477
1754-9485
Publication date 2013-02-01
Year available 2012
Sub-type Article (original research)
DOI 10.1111/j.1754-9485.2012.02463.x
Volume 57
Issue 1
Start page 97
End page 104
Total pages 8
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2013
Language eng
Formatted abstract
Introduction: Definitive treatment with concurrent cisplatin and radiation is the standard of care for locally advanced cervix cancer. The optimal management of patients with a contraindication to cisplatin has not been established. We conducted a retrospective audit of concurrent chemotherapy in a cohort of patients with locally advanced cervix cancer.
Methods: All patients with locally advanced cervix cancer treated with definitive radiation were entered into a prospective database. Information regarding their demographics, stage, histology, recurrence and survival were recorded. Pharmacy records were reviewed to determine concurrent chemotherapy use.
Results: A total of 442 patients were included in the audit. Two hundred sixty-nine patients received cisplatin, 59 received carboplatin and 114 received no concurrent chemotherapy. Overall survival was significantly improved with the use of concurrent cisplatin compared with radiation alone (adjusted hazard ratio 0.53, P = 0.001), as was disease-free survival and rate of distant failure. The use of carboplatin was not associated with any significant benefit in terms of overall survival or disease-free survival.
Conclusion: The results of this audit are consistent with the known significant survival benefit with concurrent cisplatin chemotherapy. However, there did not appear to be any significant benefit with carboplatin although there were potential confounding factors. The available evidence in the literature would favour the use of non-platinum chemotherapy rather than carboplatin in patients with contraindications to cisplatin.
Keyword Carboplatin
Cervical cancer
Chemoradiation
Cisplatin
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online 17 October 2012

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 Mar 2013, 11:12:55 EST by System User on behalf of School of Public Health